CytoDyn Inc. (CYDY)
About CytoDyn Inc.
CYTODYN INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $0
- Net income
- $3.7M
- Total assets
- $18.0M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
CytoDyn Inc. (CYDY) Stock Price
- Profitable — net income of $3.7M in FY2023.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CytoDyn Inc..
Write a review
News about CytoDyn Inc.
News & sentiment via Polygon.io
CytoDyn Inc.: frequently asked questions
Is CytoDyn Inc. an American company?
CytoDyn Inc. is a US-based company headquartered in Vancouver, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is CytoDyn Inc. headquartered?
CytoDyn Inc. is headquartered in Vancouver, Washington, United States.
Is CytoDyn Inc. publicly traded?
Yes — CytoDyn Inc. is a publicly traded company. Its stock trades under the ticker symbol CYDY on the OTC.
What does CytoDyn Inc. do?
CytoDyn Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
